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Summary
Why do we need a review specifically addressing arte-
rial hypertension in elderly patients? First, arterial 
 hypertension prevalence increases with age and, there-
fore, a large proportion of hypertensive patients are 
 elderly patients. Despite this fact, the specific issues of 
arterial hypertension in elderly patients are only mar-
ginally debated in current guidelines. Second, there are 
physiological changes (e.g., increasing arterial stiff-
ness, reduced body water content, decreased function of 
several organ systems) and pathophysiological changes 
(e.g. increasing prevalence of comorbidities) with in-
creasing age, making diagnosis and therapy of arterial 
hypertension in elderly patients more demanding. 
Third, for some recommendations (e.g., appropriate 
target blood pressure) levels of evidence are lower than 
in younger hypertensive patients, leading to conflicting 
recommendations between guidelines. This review in-
tends to discuss some of the specific issues in elderly 
patients with arterial hypertension.
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Introduction
Several guidelines for the management of arterial 
 hypertension have been published in recent years, the 
most important being the 2013 guideline of the Euro-
pean Society of Hypertension (ESH) and the European 
Society of Cardiology (ESC) in Europe [1], the 2003 
guideline of the Joint National Committee (JNC) in the 
United States [2], and the 2011 guideline of the 
 National Institute for Health and Clinical Excellence 
(NICE) in the United Kingdom [3]. So far, there is no 
guideline specifically addressing hypertension in 
 elderly patients. However, several international socie-
ties elaborated an expert consensus document on 
 hypertension in the elderly in 2011 [4]. In Switzerland, 
the Swiss Society of Hypertension 
(SSH) regularly publishes leaflets 
containing condensed and practical 
guidelines [5].
Diagnosis
Measurement of blood pressure  
in elderly patients
For the measurement of blood pressure (BP) in elderly 
patients, the same devices as for younger patients may 
be used and the measurement is as well performed in 
the sitting position. As in the younger age group, BP 
measurement is initially performed on both upper 
arms and the arm with the higher BP value is chosen 
for the subsequent BP measurements. Inter-arm differ-
ences (defined as difference >20 mm Hg between right 
and left arm) are more frequent among elderly patients 
(prevalence approximately 20%). In contrast to younger 
patients, additional BP measurements in the standing 
position are mandatory to exclude orthostatic hypoten-
sion (best performed 1 and 3 minutes after standing up, 
see below). Of note, the oscillometric method may fail 
in patients with atrial fibrillation, a frequent problem 
in elderly hypertensive patients.
Ambulatory blood pressure monitoring (ABPM) 
should be generously used in elderly patients, because 
indications for ABPM are encountered more frequently. 
For example, white-coat hypertension is more frequent 
among elderly patients (prevalence approximately 
15%–25%) [4]. The opposite of white-coat hypertension, 
masked hypertension (i.e. higher BP at home than in 
the clinic), is also a frequent phenomenon in elderly 
 patients with an estimated prevalence of 21%–45% [6]. 
Furthermore, BP values more frequently vary between 
measurements and elderly patients more frequently 
have resistant hypertension.
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There are two important pitfalls while interpreting 
BP values: pseudohypo- and pseudohypertension. 
Pseudohypotension means the measurement of false 
low BP values distal to a stenosis that do not cor-
respond to the relevant central BP. These patients are 
at risk of being undertreated. Pseudohypertension 
means the measurement of false high BP values – a 
phenomenon which occurs if the brachial artery is stiff-
ened and the cuff is not capable of completely compress-
ing the vessel. This results in persisting Korotkoff 
sounds though the cuff pressure exceeds the intra-
vascular pressure. According to different studies, the 
prevalence of pseudohypertension in elderly patients 
ranges from 2% to 70%. These patients are at risk of be-
ing overtreated. The treating physician should always 
consider the presence of pseudohypertension if there 
are only few signs of end organ damage despite the high 
BP values or if the patient does not well tolerate anti-
hypertensive treatment. However, it is difficult to prove 
pseudohypertension without invasive BP measure-
ment. Recently, novel devices capable of noninvasively 
measuring central BP have become available. Whether 
or not these devices help to diagnose pseudohypo- and 
pseudohypertension is still an open question.
Diagnosis of arterial hypertension  
in elderly patients
The criteria for the diagnosis of arterial hypertension 
in elderly patients are identical across guidelines and 
identical to the criteria in use for younger patients. 
 Arterial hypertension is diagnosed if a mean systolic 
BP >140 mm Hg OR a mean diastolic BP >90 mm Hg 
from at least three measurements on different days is 
found [5]. The “OR” is important in elderly patients: the 
criteria are met if only systolic BP is elevated.  Although 
most young hypertensive patients also have elevated 
diastolic BP, most elderly hypertensive patients have 
elevated systolic and normal diastolic BP (i.e. isolated 
systolic hypertension, ISH). Figure 1 displays the prev-
alence of ISH according to age (data from reference [7]). 
The increasing ISH prevalence with age results from 
the loss of vessel elasticity with progressing athero-
sclerosis. The elasticity loss increases pulse wave veloc-
ity and consequently BP during late systole. Therefore, 
systolic BP increases during life, while diastolic BP 
tends to decrease after the age of 60. As a consequence 
of increasing systolic BP during life, prevalence of arte-
rial hypertension increases with age (fig. 2) [8]. After 
the age of 70, arterial hypertension is the most fre-
quent cardiovascular risk factor. One might argue that 
criteria for arterial hypertension are too strict in 
 elderly patients. However, it is appropriate to use the 
same criteria for hypertension diagnosis in young and 
old patients, because the occurrence of dangerous 
cardio vascular events in elderly patients depends on 
BP similarly to young patients [9].
Searching for secondary forms of hypertension
In general, the recommendations for searching for sec-
ondary forms of hypertension in elderly patients are 
similar to young patients. However, the treating physi-
cian has to be aware that some aetiologies of secondary 
hypertension are more frequent in elderly patients 
(e.g., renal artery stenosis, sleep apnoea), whereas oth-
ers are less common (e.g., primary aldosteronism). The 
question always arises as to whether or not to search 
for secondary forms of hypertension. This decision 
should be made individually. In general, it is recom-
mended to search for secondary hypertension forms at 
the latest, if BP treatment targets are not achieved 
 despite three antihypertensive drugs.
Searching for organ damage in elderly patients
Organ damage, caused by atherosclerosis in large and 
small arteries, is more frequent in elderly than in 
young patients. Usually, in newly diagnosed hyper-
Figure 1
Prevalence of isolated systolic hypertension (ISH) according to age (data 
from reference [7]). 
SDH = combined systolic-diastolic hypertension; IDH = isolated diastolic 
hypertension.
Figure 2
Prevalence of arterial hypertension according to age and sex  
(data from reference [8]).
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tensive patients organ damage is searched for in the 
most vital and most frequently affected organs: heart, 
kidney and eyes. An electrocardiogram (ECG), urinaly-
sis including albuminuria/microalbuminuria, and fun-
doscopy should be performed in all patients. In particu-
lar, albuminuria/microalbuminuria and fundoscopy 
point to damage in small vessels. In elderly hyper-
tensive patients, two further organs should be checked: 
brain and blood vessels. As hypertension is an impor-
tant risk factor of cognitive decline, cognitive function 
should be assessed in elderly hypertensive patients 
with the use of a suitable instrument (e.g., Mini Mental 
State Examination). The assessment of cognitive func-
tion before therapy initiation is particularly valuable 
to detect cognitive decline after therapy initiation. 
Though white matter lesions are frequently seen dur-
ing magnetic resonance imaging studies of elderly 
 hypertensive patients, imaging studies are not gener-
ally recommended because of the costs of these exami-
nations and the lack of consequences. Regarding blood 
vessels, the 2013 ESH/ESC guideline is the first to rec-
ommend the measurement of pulse wave velocity to 
 determine the degree of vessel stiffness. With the 
 recent advent of simple devices for its measurement, 
pulse wave velocity might become more important for 
estimating cardiovascular risk and effects of anti-
hypertensive therapy in the future, but more studies 
are needed in this regard.
Treatment
Evidence for treating hypertension in elderly 
patients
For patients aged 70 to 79 years, the beneficial effects 
of antihypertensive drug therapy have been evident for 
many years [10]. Up until 2008, for patients aged 80 
years and older, only subgroup analyses from large tri-
als were available [11]. These subgroup analyses sug-
gested beneficial effects of antihypertensive drug ther-
apy on important nonfatal cardiovascular events, but 
also a possible increase of all-cause mortality. The 2008 
HYVET study clarified the situation in patients aged 
80 years and older: BP lowering with the use of anti-
hypertensive drugs reduces all-cause mortality as well 
as nonfatal cardiovascular events [12]. However, as a 
limitation of this study, it has to be noted that the study 
participants were healthier than normal for this age, 
as shown by low numbers of cardiovascular risk factors 
and comorbidities. There are further studies showing 
that antihypertensive drug therapy reduces the occur-
rence of dementia [13]. It has to be recognised that all 
the trials showing the beneficial effects of antihyper-
tensive drug therapy in elderly patients have been con-
ducted in patients with systolic BP ≥160 mm Hg (grade 
2 and 3 hypertension). Thus, trials do not resolve the 
question as to whether or not to treat grade 1 hyperten-
sion (systolic BP 140–159 mm Hg, diastolic BP 90–
99 mm Hg) in elderly patients. Due to this uncertainty, 
guidelines are inconsistent regarding recommenda-
tions for treating grade 1 hypertension in elderly 
 patients. The 2011 NICE guideline is the most restric-
tive and recommends drug therapy of grade 1 hyper-
tension only in patients below the age of 80 years [3]. 
In patients aged 80 years and older, initiation of drug 
therapy is only recommended for grade 2 and 3 hyper-
tension. The 2013 ESH/ESC guideline is less restric-
tive and says that antihypertensive drug treatment 
may be considered for grade 1 hypertension [1]. The 
most relevant document regarding treatment of hyper-
tension in elderly, the 2011 expert consensus, clearly 
recommends initiation of treatment in grade 1 hyper-
tension irrespective of age [4]. Thus, in conclusion, the 
opinions whether or not to treat grade 1 hypertension 
in patients aged 80 years and older differ considerably. 
Probably, in this group of patients, treatment decisions 
should also take into consideration overall cardio-
vascular risk.
Two interesting secondary findings  
from clinical trials
First, the efficacy of antihypertensive drug therapy is 
generally higher in elderly than in younger patients: 
numbers needed to treat are lower, because the rate of 
cardiovascular events is higher in elderly patients and 
an effective therapy will therefore lead to a higher 
 absolute risk reduction than in young patients with 
low event rate. Second, the reduction of nonfatal events 
is more pronounced than the reduction of mortality. 
Consequently, antihypertensive drug therapy not only 
prolongs life, but also improves quality of life, because 
the sequelae of nonfatal events (e.g., paresis after 
stroke, heart failure after myocardial infarction) lead 
to disability and a decrease in quality of life.
Recommendations for lifestyle and drugs
Lifestyle measures are effective in elderly hyper tensive 
patients. Salt restriction seems to be particularly effec-
tive, but the difficulties of salt restriction in daily life 
are well known [14]. Weight reduction may be recom-
mended for elderly physically active patients. In 
 patients unable to train their muscles, weight reduc-
tion should not be recommended because these pa-
tients will lose muscle mass which may promote disa-
bility. Though lifestyle measures are effective, it has to 
be realised that most elderly patients have high cardio-
vascular risk and therefore qualify for early initiation 
of drug therapy. Generally speaking, antihypertensive 
drug therapy should be started earlier in elderly than 
in young patients. The 2013 ESH/ESC guideline also 
recommends considering early initiation of two-drug 
combinations in patients with marked BP elevation 
and/or high cardiovascular risk, which often applies to 
elderly patients.
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The choice of the antihypertensive drug class 
 depends on comorbidities. As the prevalence of co-
morbidities increases with age, comorbidities more 
 frequently influence the choice of drug class in elderly 
patients (table 1). Treating physicians have to be aware 
that beta blockers may increase the incidence of 
 depression, diabetes or relevant bradycardia. Diuretics 
and calcium channel blockers are often a good choice. It 
is important to know that calcium channel blockers 
may cause ankle oedema and that it is wrong to esca-
late drug therapy by adding a diuretic to treat the 
 ankle oedema. In such a situation, the calcium channel 
blocker should be replaced by a calcium channel blocker 
less likely to cause ankle oedema or by another drug 
class. Initiating drug therapy with half of the usual 
dose (in accordance with “start low, go slow”) is appro-
priate in many elderly patients. However, it is impor-
tant to increase to the usual dose if BP treatment tar-
gets are not achieved.
BP treatment targets in elderly patients
BP treatment targets in elderly patients are controver-
sial (similar to the BP levels giving rise to the initiation 
of antihypertensive treatment, see above), which is the 
consequence of a lack of clear evidence from clinical tri-
als. As denoted above, all clinical trials were conducted 
in patients with systolic BP ≥160 mm Hg before ther-
apy initiation. In most trials, the mean BP reduction 
during treatment was in a range of 10 to 20 mm Hg. 
Therefore, it is unclear whether systolic BP should be 
reduced below 140 mm Hg in all elderly patients. The 
restrictive 2011 NICE guideline recommends a BP 
treatment target of <150/90 mm Hg in patients aged 
80 years and older and <140/90 mm Hg in patients 
younger than 80 years [3]. The 2011 expert consensus 
documents generally recommends a BP treatment tar-
get <140/90 mm Hg irrespective of age, but adds that a 
BP of 140 to 145 mm Hg may be acceptable in some 
 patients after the age of 80 [4]. The 2013 ESH/ESC 
guideline generally recommends reducing systolic BP 
to between 140 and 150 mm Hg in patients aged less 
than 80 years, but also states that systolic BP <140 mm 
Hg may be considered in fit elderly patients aged less 
than 80 years [1]. For patients older than 80 years, the 
2013 ESH/ESC guideline recommends reducing sys-
tolic BP to between 140 and 150 mm Hg provided they 
are in good physical and mental conditions.
The problem of critical organ perfusion
Is there a rationale to recommend different BP treat-
ment targets for young and elderly patients? Yes, there 
is. As atherosclerosis progresses during aging, stenoses 
may develop in large and small vessels. If the central 
BP is reduced by antihypertensive treatment, organ 
perfusion may become critical distal to the stenosis. 
Critical organ perfusion may have serious conse-
quences in three organs, the heart, the kidneys and the 
brain. In the heart, myocardial ischaemia may be the 
result and is probably the main reason for the observed 
increase in mortality if BP is reduced below 130/65 
mm Hg (J-curve phenomenon). The 2011 expert con-
sensus document therefore recommends not to lower 
BP <130/65 mm Hg after the age of 80 [4]. Thus, a dias-
tolic BP <65 mm Hg, renal failure and/or a decline of 
cognitive function may be adequate reasons why in 
some patients a systolic target BP >140 mm Hg has to 
be accepted. Regarding kidneys, physicians generally 
are trained to check the renal function 1 to 3 weeks 
 after an intensification of antihypertensive treatment, 
in particular after the initiation of a drug treatment 
with angiotensin converting-enzyme (ACE) inhibitors 
or angiotensin receptor blockers. Regarding brain, phy-
sicians should increase their awareness of assessing 
cognitive function before and after initiation of anti-
hypertensive treatment.
Table 1
Preferred antihypertensive drug class according to comorbidities.
Comorbidities Preferred antihypertensive drug class
No comorbidities Diuretic, ACE inhibitor / angiotensin receptor blocker, calcium channel blocker
Coronary artery disease Beta blocker, ACE inhibitor / angiotensin receptor blocker
Angina pectoris Beta blocker, calcium channel blocker
Hypertensive heart disease ACE inhibitor / angiotensin receptor blocker
Aortic stenosis Diuretic
Mitral regurgitation ACE inhibitor / angiotensin receptor blocker
Heart failure Diuretic, ACE inhibitor / angiotensin receptor blocker, beta blocker,  
aldosterone antagonist
Tachyarrhythmia Beta blocker, (verapamil-type) calcium channel blocker
Peripheral arterial disease Calcium channel blocker
Diabetes mellitus ACE inhibitor / angiotensin receptor blocker, calcium channel blocker
Chronic renal failure ACE inhibitor / angiotensin receptor blocker, calcium channel blocker
Prostatic hyperplasia Alpha-blocker
ACE = angiotensin converting-enzyme
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The problem of orthostatic hypotension
Orthostatic hypotension is defined as a decrease of sys-
tolic BP ≥20 mm Hg and/or diastolic BP ≥10 mm Hg on 
standing. The risk of orthostatic hypotension is 
 increased in elderly hypertensive patients (prevalence 
approximately 5%–10%), in particular after the initia-
tion of antihypertensive treatment. The increased risk 
is a consequence of stiffer vessel walls, a decreased 
intra vascular blood volume and autonomic dysfunction 
in older age. Therefore, additional BP measurements in 
the standing position before as well as during therapy 
are mandatory in elderly patients to exclude orthos-
tatic hypotension. The measurements are best per-
formed 1 and 3 minutes after standing up. The pres-
ence of orthostatic hypotension may have two con-
sequences: first, a reduced adherence to the prescribed 
drug regimen; second, an increased risk of falls. As falls 
may have serious consequences in elderly patients, 
ortho static hypotension may be an adequate reason 
why in some patients a systolic target BP >140 mm Hg 
has to be accepted.
The problem of reduced life expectancy
There is general agreement that the decision whether 
or not to treat hypertension with drugs should also con-
sider remaining life expectancy. It is commonly ac-
cepted not to treat arterial hypertension in patients 
with markedly reduced life expectancy (below 1 to 
2 years), but such decisions should be made individu-
ally and take into consideration potential benefits and 
risks.
Why multidimensional geriatric assessment  
is important
Geriatric assessment is a multidimensional and inter-
disciplinary diagnostic process to determine an elderly 
person’s medical, psychosocial, and functional capacity 
and problems with the objective of developing an over-
all plan for treatment and follow-up. Geriatric assess-
ment includes usual patient history, usual diagnostic 
tests (such as laboratory findings) as well as specific 
tests for the evaluation of cognition, mobility, risk of 
falls, nutrition, emotional status and other domains. 
Most of these domains are very relevant in elderly 
 hypertensive patients. The assessment of cognition in 
elderly hypertensive patients is relevant mainly for 
two reasons: first, cognition may deteriorate during 
 antihypertensive treatment and the treating physician 
should recognise such a deterioration; second, patients 
with cognitive limitations, in particular patients with 
nonobvious, only moderate cognitive limitations, are 
prone to nonadherence and the treating physician 
should be aware of this circumstance to ensure adher-
ence to antihypertensive drugs. The assessment of mo-
bility and risk of falls is important, because antihyper-
tensive drugs, in particular diuretics, may increase risk 
of falls [15]. As some antihypertensive drugs also may 
have effects on nutrition and emotional status, these 
two domains should also be assessed before and during 
antihypertensive treatment. Furthermore, mobility 
and nutritional assessment may help the treating phy-
sician to decide whether lifestyle recommendations 
such as weight reduction or physical activity are feasi-
ble.
Final remarks
It is important to realise that differences in biological 
age increase with increasing chronological age. There-
fore, chronological age is, in general, not a good marker 
on which decisions should be based. Nevertheless, 
many guidelines use chronological age to distinguish 
recommendations. This is problematic. There are 
healthy and less healthy elderly people. Probably anti-
hypertensive treatment should be identical to that of 
young patients in healthy elderly people, irrespective 
of chronological age, whereas for less healthy elderly 
people different recommendations may be justified. 
Furthermore, many of the guideline recommendations 
differing between young and elderly patients are not 
supported by scientific evidence. The differing recom-
mendations are only the result of a scientific black hole. 
Hopefully, future research will help to answer the open 
questions. Last but not least, antihypertensive treat-
ment does not only prolong life. It is one of the most 
 effective measures to improve quality of life and to 
 reduce disability and nursing home admissions in 
 elderly patients. Nevertheless, BP is currently brought 
to recommended target levels in less than one-half of 
patients. Let us hope that this proportion may be in-
creased in the near future!
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